Cardiovascular Outcomes in Adults with Coronary Artery Disease and Obstructive Sleep Apnea with vs without Excessive Daytime Sleepiness in the RICCADSA Cohort - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36800433/
Adverse cardiovascular outcomes did not differ by levels of EDS for CAD patients with OSA, who were untreated or non-adherent to treatment. CPAP use, at least 4 hours/night, was associated...
Conclusions: Adverse cardiovascular outcomes did not differ by levels of EDS for CAD patients with OSA, who were untreated or non-adherent to treatment. CPAP use, at least 4 hours/night, was associated with reduced adverse outcomes in participants without EDS.
Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36786121/
Insomnia disorder is considered as a stress-related disorder associated with hyperarousal, stress and emotion dysregulation and the instability of the 'flip-flop' switch system. The orexinergic system is well known for...
Conclusions: Taken together these findings may let us hypothesise that an orexins overactivation may be associated with stress-related hyperarousal and the hyperactivation of arousal-promoting systems in insomnia. On the other hand, it is possible that by rebalancing orexins with DORAs we may regulate both sleep and allostatic systems, in turn,...
Daridorexant
Source : https://www.ncbi.nlm.nih.gov/books/NBK576872/
No information is available on the use of daridorexant during breastfeeding. Because it is about 99.7% bound to plasma proteins, amounts in milk are likely to be small. If daridorexant...
Conclusions: No information is available on the use of daridorexant during breastfeeding. Because it is about 99.7% bound to plasma proteins, amounts in milk are likely to be small. If daridorexant is required by the mother, it is not a reason to discontinue breastfeeding. However, until more data become available, an alternate drug may be...
Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36800596/
Different dosages of daridorexant were tested for treatment of insomnia; however, 5 and 10 mg are not available because of issues of suboptimal effectiveness. Daridorexant showed better efficacy and safety...
Conclusions: Different dosages of daridorexant were tested for treatment of insomnia; however, 5 and 10 mg are not available because of issues of suboptimal effectiveness. Daridorexant showed better efficacy and safety for treatment of insomnia disorder at doses of 25 and 50 mg.
Daridorexant in Insomnia Disorder: A Profile of Its Use - CNS Drugs
Source : https://link.springer.com/article/10.1007/s40263-023-00987-9
Daridorexant (Quviviq™) is a useful option for the treatment of insomnia disorder, which has shown efficacy in younger and older adults. It antagonises the orexin receptors, thereby reducing the wake...
Conclusions: The efficacy of daridorexant was maintained during a 12-month extension trial, with no new safety or tolerability concerns.
-
Sleep Disorder Connect3yrKey Points • Source: CNS Drugs • Conclusions/Relevance: “Daridorexant (Quviviq) is a useful option for the treatment of insomnia disorder, which has shown efficacy in younger and older adults. It antagonises the orexin receptors, Show More